Replimune Group (NASDAQ:REPL) Trading Down 7.6% – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL)’s stock price fell 7.6% on Monday . The stock traded as low as $9.63 and last traded at $9.60. 342,987 shares were traded during trading, a decline of 52% from the average session volume of 712,642 shares. The stock had previously closed at $10.39.

Analyst Upgrades and Downgrades

REPL has been the topic of several recent analyst reports. HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. BMO Capital Markets lifted their target price on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group increased their price target on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The firm’s 50 day moving average is $12.60 and its 200-day moving average is $12.14. The stock has a market capitalization of $663.87 million, a price-to-earnings ratio of -2.81 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Institutional Trading of Replimune Group

Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in Replimune Group by 352.5% in the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company’s stock valued at $13,282,000 after purchasing an additional 854,346 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Replimune Group by 25.9% during the 4th quarter. California State Teachers Retirement System now owns 42,725 shares of the company’s stock worth $517,000 after buying an additional 8,793 shares in the last quarter. Woodline Partners LP boosted its position in Replimune Group by 156.6% in the 4th quarter. Woodline Partners LP now owns 854,309 shares of the company’s stock valued at $10,346,000 after buying an additional 521,366 shares during the period. Velan Capital Investment Management LP acquired a new position in shares of Replimune Group in the fourth quarter worth $2,196,000. Finally, Soleus Capital Management L.P. purchased a new stake in shares of Replimune Group during the fourth quarter worth $3,179,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.